At a glance
- Originator Kissei Pharmaceutical
- Class Calcium regulators; Coumarins; Isoflavones; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis